Treatment of symptomatic posterior vitreous detachment via YAG laser vitreolysis. Eye Diseases
Conditions
Interventions
Randomization was achieved by employing a random number for each patient, 1 for treatment and 2 for control. Patients in treatment group will be dilated with phenylephrine 2.5% and tropicamide 1% and
Sponsors
Harbin Aier Eye Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 14/11/2022: 1. Symptomatic vitreous opacities owing to complete PVD (Weiss ring), symptoms for at least 3 months 2. No sensation of flashing for at least 2 weeks 3. Clear optical media 4. The distance between floaters and retina or lens was over 3mm (measured by B-scan ultrasound) 5. The 10-point visual disturbance score of at least 4 6. Ability to undertake YAG laser procedure 7. Acceptance of related risks _____ Previous inclusion criteria: 1. Symptomatic vitreous opacities owing to complete PVD (Weiss ring), symptoms for at least 3 months 2. Clear optical media 3. The distance between floaters and retina or lens was over 3mm (measured by B-scan ultrasound) 4. The 10-point visual disturbance score at least 4 5. Ability to undertake YAG laser procedure 6. Acceptance of related risks
Exclusion criteria
Exclusion criteria: Current exclusion criteria as of 11/11/2022: 1. Snellen BCVA was worse than 20/50 2. Patients with a history of glaucoma, severe cataract, vitreous hemorrhage, retinal disease, macular disease. _____ Previous exclusion criteria as of 18/10/2022: 1. Snellen BCVA was worse than 20/50 2. Less than 50% of the Weiss ring was ablated after one treatment (objective changes were evaluated by the surgeon who performed the YAG laser vitreolysis); patients with a history of glaucoma, severe cataract, vitreous hemorrhage, retinal disease, macular disease. _____ Previous exclusion criteria: 1. Snellen BCVA was worse than 20/50 2. Eyes with intraocular lens (IOL) 3. Less than 50% of the Weiss ring was ablated after one treatment (objective changes were evaluated by the surgeon who performed the YAG laser vitreolysis); patients with a history of glaucoma, severe cataract, vitreous hemorrhage, retinal disease, macular disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At preoperative, postoperative week 1, month 1, month 3 and month 6: 1. Visual disturbance measured using a 10-point visual disturbance score (with 0 being asymptomatic and 10 indicating impairing symptoms) 2. Degree of patients disturbed by floaters measured using a short questionnaire of 4-degree floater symptoms 3. Symptoms improvement percentage measured using a 4-level qualitative scale | — |
Secondary
| Measure | Time frame |
|---|---|
| At preoperative, postoperative week 1, month 1, month 3 and month 6: 1. The National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25) 2. Best corrected visual acuity (BCVA) | — |
Countries
China
Outcome results
None listed